Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

, , , , ,,
Future Oncology
Erasmus University Rotterdam

Kuppen, M.C. (Malou Cp), Westgeest, H.M, van der Doelen, M.J. (Maarten J.), van den Eertwegh, A.J. (Alphonsus Jm), Coenen, J.L.L.M, Aben, K.K.H, … Gerritsen, W.R. (2020). Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 16(19), 1371–1384. doi:10.2217/fon-2020-0039